washington  reuters    u s  senate republican leader mitch mcconnell told reuters on wednesday he expects bipartisan support for approval of a bill authorizing taxpayer and industry funding for the u s  food and drug administration  the bill to reauthorize the prescription drug user fee act would let the fda continue to collect hundreds of millions of dollars from drugmakers and medical device companies to partially cover the cost of reviewing new products  with u s  taxpayers funding the remainder   it s an extremely important bill that i think we ll be able to move on a bipartisan basis   mcconnell said in an interview   the fda has been charging companies to review their products since   on tuesday  president donald trump proposed in his  budget that the industry pay the full cost of drug and medical device reviews   the industry at present pays about  percent  that proposal is unlikely to be approved in this cycle  reauthorization of the user fee bill is typically negotiated between the fda and industry over a period of several years  earlier this month  the bill was approved by a senate panel by a   vote  it must be renegotiated every five years  the fda reviews drugs for approval or rejection for many companies  including major ones such as pfizer inc  merck   co inc and johnson and johnson  pharmaceutical companies based overseas  including roche holding ag and novartis ag  also pay these fees for u s  approved drugs 